Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: ShatPlus along with standard treatment: 10 ml thrice a day ShatPlus along with standard treatment
Control Intervention1: Standard treatment: Standard treatment as per protocol of ICMR
Sponsors
BVG Life Sciences Ltd BVG Group
Eligibility
Inclusion criteria
Inclusion criteria: SARS-CoV-2 positive nasopharyngeal swab Mild to Moderately severe disease (NEWS score Signed informed consent must be obtained and documented according to AYUSH GCP, and national/local regulations
Exclusion criteria
Exclusion criteria: Requiring ICU admission at screening History of MI, Epileptic episodes Any other comorbidity which is at critical stage at screening Any other condition by which subject proves unfit from investigator perspective
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| No. of days for negative PCR confirmatory test from nasopharyngeal swab for SARS-Covid 2 Serum levels of CD4, CD8, NK cell panel CD16/CD56, CRP, IgM, IgGTimepoint: From baseline to end of study ie 10 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical status of severity Change in National Early Warning Score Hematological parameters like WBS, RBC and platelet count etc. Change in clinical symptom presentation No. of days for negative PCR confirmatory test for SARS-Covid 2 Requirement of admission to intensive care unit Duration of hospital admission Total days admitted to the hospitalTimepoint: From baseline to end of study ie 10 days | — |
Countries
India
Contacts
Public ContactDr Pawan Kumar Singh
BVG Life Sciences Ltd. (BVG Group)
Outcome results
None listed